Atypical hemolytic-uremic syndrome: Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
(6 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
+ | ==Background== |
||
⚫ | |||
+ | *One of the [[thrombotic microangiopathy|thrombotic microangiopathies]] |
||
⚫ | |||
+ | *Different pathophysiology and treatment from [[hemolytic-uremic syndrome|typical hemolytic-uremic syndrome]] (after STEC diarrhea) and [[secondary hemolytic-uremic syndrome]] |
||
⚫ | |||
− | == Investigations == |
||
⚫ | |||
⚫ | |||
+ | *Mutations can occur anywhere in the complement pathway or, occasionally, in unrelated proteins |
||
+ | **Complement factor H (CFH), C3, factor B, factor I, CD46 |
||
+ | **Diacylglycerol kinase ε, plasminogen, factor XII (in the presence of anti-factor H autoantibodies), and thrombomodulin (CD141) |
||
− | == |
+ | ==Diagnosis== |
⚫ | |||
⚫ | |||
+ | |||
⚫ | |||
+ | ==Management== |
||
− | * Eculizumab |
||
+ | |||
⚫ | |||
⚫ | |||
+ | **[[Eculizumab]] to inhibit C5 complement |
||
+ | **Ideally with full meningococcal vaccination beforehand |
||
[[Category:Hematology]] |
[[Category:Hematology]] |
||
[[Category:Nephrology]] |
[[Category:Nephrology]] |
||
+ | [[Category:Thrombosis]] |
Latest revision as of 09:50, 20 April 2023
Background
- One of the thrombotic microangiopathies
- Different pathophysiology and treatment from typical hemolytic-uremic syndrome (after STEC diarrhea) and secondary hemolytic-uremic syndrome
Pathophysiology
- Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity
- Mutations can occur anywhere in the complement pathway or, occasionally, in unrelated proteins
- Complement factor H (CFH), C3, factor B, factor I, CD46
- Diacylglycerol kinase ε, plasminogen, factor XII (in the presence of anti-factor H autoantibodies), and thrombomodulin (CD141)
Diagnosis
- Genetic mutation analysis of complement regulatory proteins (CFH, CFI, MCP, C3, CFB, THBD) and anti-CFH antibodies
Management
- Often unable to distinguish from TTP, so plasma exchange should be initiated promptly
- If no improvement on PLEX and there is significant renal involvement, consider:
- Eculizumab to inhibit C5 complement
- Ideally with full meningococcal vaccination beforehand